Novo Nordisk, obesity and REDEFINE
Novo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight and type 2 diabetes in the REDEFINE 2 trial
Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating once-weekly subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.
Novo Nordisk’s vision of 25%-plus weight loss is looking further and further away. | Novo Nordisk’s vision of 25%-plus weight ...
Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type-2 diabetes. However, when the drugs are ...
Lars Fruergaard Jørgensen might not be a household name, but his company’s drug is. And its success has thrust him — ...
Discover the latest experimental obesity drug from Novo Nordisk, achieving 15.7% weight loss after 68 weeks, which fell short of the company's expectations.
If you want to address civilization and society's issues, then you have to do it with the city," Urban Partners' co-CEO Claus ...
Novo Nordisk is not concerned by the ongoing US trade war and the 25% tariff set to go into effect for pharmaceutical ...
Leading Russian drugmakers PSK Pharma and Promomed, which produce the analogues of Ozempic - a drug for the treatment of ...
Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, DK-2300 Copenhagen ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback